These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 3842691)

  • 21. Biological indicator test packs: a survey of user practices.
    Smith DE
    J Healthc Mater Manage; 1988; 6(4):38, 40-2. PubMed ID: 10287653
    [No Abstract]   [Full Text] [Related]  

  • 22. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 23. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 24. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract]   [Full Text] [Related]  

  • 25. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
    Goujard J
    Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
    [No Abstract]   [Full Text] [Related]  

  • 28. [Industrial drug-surveillance. Spontaneous notification: data collection, survey].
    Trunet P
    Rev Med Interne; 1986 Nov; Spec No():35-9. PubMed ID: 3809778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 31. Postmarketing studies of drug efficacy.
    Strom BL; Melmon KL; Miettinen OS
    Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
    [No Abstract]   [Full Text] [Related]  

  • 32. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug nephrotoxicity. A microcomputerized databank of renal involvement and responsible "nephrotox" drugs].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1988 May; 43(3):211-7. PubMed ID: 3420569
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 36. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 37. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
    Kingston R
    Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
    [No Abstract]   [Full Text] [Related]  

  • 38. [Notification of possible adverse reactions to drugs in medical publications].
    Laporte JR; Capellà D
    Med Clin (Barc); 1984 Oct; 83(11):474. PubMed ID: 6503426
    [No Abstract]   [Full Text] [Related]  

  • 39. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry.
    Hum Reprod; 1987 Apr; 2(3):241-63. PubMed ID: 3597744
    [No Abstract]   [Full Text] [Related]  

  • 40. [Postmarketing surveillance of drugs].
    Simon P; Soubrié C
    Rev Prat; 1983 Jan; 33(1-2):23-8. PubMed ID: 6823538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.